financetom
Business
financetom
/
Business
/
MEG Energy Meets Q3 Earnings and Revs Forecasts Even As Both Decline Amid Takeover Saga It Was at the Heart Of; 2025 Outlook Maintained
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MEG Energy Meets Q3 Earnings and Revs Forecasts Even As Both Decline Amid Takeover Saga It Was at the Heart Of; 2025 Outlook Maintained
Nov 10, 2025 3:24 PM

05:45 PM EST, 11/10/2025 (MT Newswires) -- MEG Energy ( MEGEF ) , after market close on Monday, said its third-quarter profit and revenue declined slightly, and that is reiterating its 2025 operating and capital outlook.

For Q3, MEG earned $159 million, or $0.62 per diluted share, down from $167 million, or $0.62 per diluted share, a year ago. FactSet had expected $0.62 per share. MEG said the decline was "primarily driven by an unrealized foreign exchange loss and transaction costs in 2025 related to the Strathcona unsolicited offer and the Cenovus plan of arrangement partially offset by lower depletion and depreciation."

Revenue fell to $1.18 billion from $1.27 billion in the year-ago quarter. FactSet projected $1.18 billion.

MEG Energy ( MEGEF ) is in the process of being taken over by Cenovus Energy ( CVE ) , which looks to have beaten off a rival challenge from Strathcona Resources ( STHRF ) for MEG.

The company reaffirmed its 2025 operating and capital spending guidance, first released on Nov. 25, 2024. It continues to expect capital expenditures of $635 million and forecasts average bitumen production between 95,000 and 105,000 barrels per day for the year. Non-energy operating costs are projected to range between $5.30 and $5.80 per barrel.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Silver Bullet Mines Ships First Commercial Quantity of Gold And Silver Concentrate
Silver Bullet Mines Ships First Commercial Quantity of Gold And Silver Concentrate
Oct 24, 2025
01:57 PM EDT, 10/24/2025 (MT Newswires) -- Silver Bullet Mines ( SBMCF ) on Friday said it shipped its first commercial quantity of gold and silver concentrate from the KT Mine in Arizona and confirms no tariff issues are expected with the shipment. The company, which expects to make concentrate shipments regularly, also plans to increase the quantity and frequency...
Ford Could Become 'Compelling' Story in 2026 if EV Losses Improve, RBC Says
Ford Could Become 'Compelling' Story in 2026 if EV Losses Improve, RBC Says
Oct 24, 2025
02:05 PM EDT, 10/24/2025 (MT Newswires) -- Ford's (F) third-quarter results were strong, though the automaker must arrest continued losses in its electric-vehicle business to become a compelling story in 2026, RBC Capital Markets said in a note e-mailed Friday. Late Thursday, Ford reported third-quarter adjusted earnings of $0.45 a share, down from $0.49 a year earlier, while revenue rose...
Vivakor Prices $3.5 Million Direct Securities Offering
Vivakor Prices $3.5 Million Direct Securities Offering
Oct 24, 2025
02:05 PM EDT, 10/24/2025 (MT Newswires) -- Vivakor ( VIVK ) priced a direct offering of common stock and prefunded warrants to a single institutional investor, aiming to raise $3.5 million. The offering, expected to close around Monday, includes 10.9 million shares and 5 million warrants, the company said Friday in a statement. Price: 0.31, Change: +0.05, Percent Change: +19.72...
Syndax's Revumenib Gets FDA Approval for Acute Myeloid Leukemia
Syndax's Revumenib Gets FDA Approval for Acute Myeloid Leukemia
Oct 24, 2025
01:51 PM EDT, 10/24/2025 (MT Newswires) -- Syndax's (SNDX) revumenib was approved by the US Food and Drug Administration as a treatment for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, the regulator said Friday. The drug was approved for use in adults and children at least one year old who have no satisfactory alternative treatment options,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved